Frontotemporal dementia patients with extrapyramidal symptoms have brainstem atrophy and reduced metabolism in certain areas of the brain significantly more often than patients without extrapyramidal ...
Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...
This study investigated the 1-year incidence of extrapyramidal symptoms (EPS), as well as the incremental economic burden, in patients with schizophrenia initiating atypical antipsychotics. Objectives ...
Caplyta’s most recent FDA approval is based on positive results from two Phase III clinical trials: Study 501 (NCT04985942) and Study 502 (NCT05061706). Both studies met their primary endpoint and key ...
Depression with anxiety disorder started in summer of 2004. From 28/7/2004 to 22/11/2004 (4 months) the patient was taking Citalopram 20 mg per day and Alprazolam 0.5 mg three times per day. On ...
Credit: Getty Images. Extrapyramidal symptoms that developed in patients with schizophrenia after initiation of treatment with atypical antipsychotic agents were associated with increased healthcare ...
To the Editor: In the Current Concepts in Therapy, "Complications from Psychotherapeutic Drugs. I.," which appeared in the February 9 issue of the Journal, reference was made to the treatment tretment ...
The approval of medicines called second-generation antipsychotics has allowed major depressive disorder (MDD) and other conditions linked to it to be treated. A person with MDD is usually prescribed ...
The approval of medicines called second-generation antipsychotics has allowed bipolar I and some conditions that come with it to be treated. A person who has bipolar I disorder can go through various ...
Cases J. 2010;3:47 © 2010 Tsolaki et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback